These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 19258280

  • 21. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP.
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
    [Abstract] [Full Text] [Related]

  • 22. Expression of Pseudomonas aeruginosa multidrug efflux pumps MexA-MexB-OprM and MexC-MexD-OprJ in a multidrug-sensitive Escherichia coli strain.
    Srikumar R, Kon T, Gotoh N, Poole K.
    Antimicrob Agents Chemother; 1998 Jan; 42(1):65-71. PubMed ID: 9449262
    [Abstract] [Full Text] [Related]

  • 23. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
    Hocquet D, Muller A, Blanc K, Plésiat P, Talon D, Monnet DL, Bertrand X.
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1173-5. PubMed ID: 18180356
    [Abstract] [Full Text] [Related]

  • 24. MexXY efflux pump overexpression and aminoglycoside resistance in cystic fibrosis isolates of Pseudomonas aeruginosa from chronic infections.
    Singh M, Yau YCW, Wang S, Waters V, Kumar A.
    Can J Microbiol; 2017 Dec; 63(12):929-938. PubMed ID: 28922614
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.
    Hocquet D, Nordmann P, El Garch F, Cabanne L, Plésiat P.
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1347-51. PubMed ID: 16569851
    [Abstract] [Full Text] [Related]

  • 27. An efflux pump (MexAB-OprM) of Pseudomonas aeruginosa is associated with antibacterial activity of Epigallocatechin-3-gallate (EGCG).
    Kanagaratnam R, Sheikh R, Alharbi F, Kwon DH.
    Phytomedicine; 2017 Dec 01; 36():194-200. PubMed ID: 29157815
    [Abstract] [Full Text] [Related]

  • 28. Role of the MexEF-OprN efflux system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin.
    Llanes C, Köhler T, Patry I, Dehecq B, van Delden C, Plésiat P.
    Antimicrob Agents Chemother; 2011 Dec 01; 55(12):5676-84. PubMed ID: 21911574
    [Abstract] [Full Text] [Related]

  • 29. MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin.
    Hocquet D, Roussel-Delvallez M, Cavallo JD, Plésiat P.
    Antimicrob Agents Chemother; 2007 Apr 01; 51(4):1582-3. PubMed ID: 17220417
    [No Abstract] [Full Text] [Related]

  • 30. Mutations in Gene fusA1 as a Novel Mechanism of Aminoglycoside Resistance in Clinical Strains of Pseudomonas aeruginosa.
    Bolard A, Plésiat P, Jeannot K.
    Antimicrob Agents Chemother; 2018 Feb 01; 62(2):. PubMed ID: 29133559
    [Abstract] [Full Text] [Related]

  • 31. Mutations in NalC induce MexAB-OprM overexpression resulting in high level of aztreonam resistance in environmental isolates of Pseudomonas aeruginosa.
    Braz VS, Furlan JP, Fernandes AF, Stehling EG.
    FEMS Microbiol Lett; 2016 Aug 01; 363(16):. PubMed ID: 27412168
    [Abstract] [Full Text] [Related]

  • 32. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously.
    Llanes C, Hocquet D, Vogne C, Benali-Baitich D, Neuwirth C, Plésiat P.
    Antimicrob Agents Chemother; 2004 May 01; 48(5):1797-802. PubMed ID: 15105137
    [Abstract] [Full Text] [Related]

  • 33. Chlorhexidine leads to the evolution of antibiotic-resistant Pseudomonas aeruginosa.
    Tag ElDein MA, Yassin AS, El-Tayeb O, Kashef MT.
    Eur J Clin Microbiol Infect Dis; 2021 Nov 01; 40(11):2349-2361. PubMed ID: 34169445
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Role of efflux pump inhibitor in decreasing antibiotic cross-resistance of Pseudomonas aeruginosa in a burn hospital in Iran.
    Talebi-Taher M, Majidpour َ, Gholami A, Rasouli-Kouhi S, Adabi M.
    J Infect Dev Ctries; 2016 Jun 30; 10(6):600-4. PubMed ID: 27367008
    [Abstract] [Full Text] [Related]

  • 36. Knock-out of multidrug efflux pump MexXY-OprM results in increased susceptibility to antimicrobial peptides in Pseudomonas aeruginosa.
    Neidig A, Strempel N, Waeber NB, Nizer WSDC, Overhage J.
    Microbiol Immunol; 2023 Sep 30; 67(9):422-427. PubMed ID: 37424105
    [Abstract] [Full Text] [Related]

  • 37. Measurement of Pseudomonas aeruginosa multidrug efflux pumps by quantitative real-time polymerase chain reaction.
    Yoneda K, Chikumi H, Murata T, Gotoh N, Yamamoto H, Fujiwara H, Nishino T, Shimizu E.
    FEMS Microbiol Lett; 2005 Feb 01; 243(1):125-31. PubMed ID: 15668010
    [Abstract] [Full Text] [Related]

  • 38. Primary mechanisms mediating aminoglycoside resistance in the multidrug-resistant Pseudomonas aeruginosa clinical isolate PA7.
    Morita Y, Tomida J, Kawamura Y.
    Microbiology (Reading); 2012 Apr 01; 158(Pt 4):1071-1083. PubMed ID: 22282519
    [Abstract] [Full Text] [Related]

  • 39. MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa.
    Mao W, Warren MS, Lee A, Mistry A, Lomovskaya O.
    Antimicrob Agents Chemother; 2001 Jul 01; 45(7):2001-7. PubMed ID: 11408215
    [Abstract] [Full Text] [Related]

  • 40. Inner membrane efflux components are responsible for beta-lactam specificity of multidrug efflux pumps in Pseudomonas aeruginosa.
    Srikumar R, Li XZ, Poole K.
    J Bacteriol; 1997 Dec 01; 179(24):7875-81. PubMed ID: 9401051
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.